chrisvoncsefalvay/vaers-outcomes huggingface dataset:
W/in 20min of vax pt devel nausea, dizziness & diaphoresis; later that day exp pain @inject site; w/in 24hrs had "vague complaints of myalgia"; w/in a week devel diffuse rash & low grade fever; 21OCT90 exp joint aches, facial pain; see worm
This spontaneous report as received from a licensed practical nurse refers to an unspecified number of patients of unknown demographics. No concurrent conditions or medical history were provided. On unknown dates, those patients were vaccinated with improperly stored doses of VAQTA injection (lot # L023232 with expiry date: 25-FEB-2017 and lot # L023936 with expiry date: 15-MAY-2017; strength, dose, route and site of administration were unspecified). The administered vaccines underwent the temperature excursion at 25 degree Fahrenheit for 11 hours and at 50 degree Fahrenheit for 3 hours 26 minutes. There was no previous temperature excursion. It was a case of a "data logger". No concomitant medications were reported. No adverse effect reported. This is one of several reports from the same source. Additional information has been requested.
Decreased sensation in the L side of the face; This is a spontaneous report from a contactable nurse (patient). A 41-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: Ek9231), intramuscular via the left arm on 30Dec2020 18:00 at a single dose for COVID-19 immunization. Medical history was none. Concomitant medication included ciprofloxacin. It was reported that the patient experienced decreased sensation in the L side of the face that lasted 3 days initially and now comes and goes on 30Dec2020 21:00. No treatment was given for the event. The outcome of the event was not recovered.
12 year old client received HPV9 at off-site clinic at 11:00am. Client reported feeling "weird" at 11:03am. 7-Up and cold compress given, moved near door for fresh air. After 15 minutes, issue unresolved. Client referred to Paramedic on site. Paramedic administered O2, monitored vital signs with client in chair. Paramedic noted irregular heartbeat via EKG. After 40 minutes of monitoring and assessment, paramedic recommended transport to Hospital. MOC declined and transported client herself. Per follow up with MOC by telephone on 7/11/17, no treatment required at Emergency Room or further follow up required.
Child was ordered to receive an MMR & Varicella separately. Child received Proquad (MMR + VARICELLA) and Varicella.
Sudden appearance of 2-inch red spot surrounding vaccination site on shoulder. Was not present until the day indicated, 10 days after administration.
Severe joint pain in right knee which is the worst site of pre-existing osteoarthritis pain
Left arm went completely numb within minutes of receiving injection. Numbness did not go away for several hours, arm remained painfully sore for 3 days afterwards. 2 days after receiving the injection, the area underneath my left eye became painfully swollen and persisted for 4 days. Once the left eye cleared up, the area underneath my right eye became painfully swollen which lasted for 2 days.
Approximately 9 days post vax the pt experienced red bumps near the injection site. The lesions became somewhat vesicular with surrounding erythema. 4 days later the pt experienced lesions on the left mid back and pruritus. 8 days post onset the lesions were crusted.
pt recv vax 1DEC95 & 2DEC95 pt devel large swelling,induration,redness & tenderness @ inj site w/red streaks about 12cm in diameter;sx inc over a 48hrs period & then peaked @ 72hrs;
Pt. received vaccines KINRIX and PROQUAD 8/18 - 8/20/16 in office with red, blistered vaccine sites. (2.5 x 2.5 inches of redness with 1 x .75 inches of blistered area) lower  vaccine site. Dr also reports area of eschar in center. Rc'd AUGMENTIN.
Nasal congestion; Sore throat; Fatigue; This is a spontaneous report from a non-contactable consumer, the patient. A 27-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications taken within two weeks were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. On an unknown date, the patient experienced nasal congestion, sore throat and fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events nasal congestion, sore throat and fatigue was unknown at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
This is a medication error.  Administered Intramuscularly. No adverse reaction noted.  Note From administering RN.   "Late note 6/26/23. Pt requested vax Lt IM. Has  hx keloid w/lst mpox vax & States PCP told to ask for 2nd dose IM. Large keloid noted on arm. Onsite county rep ok w/ change  to IM & Cited research that IM just as effective. Done Lt arm IM."
Received flu shot Friday mid-afternoon. By late Friday afternoon had strong headache and took 2 Tylenol, then another 2 Tylenol before bed. Sat/sun took 2 Aleve which only took the edge off.
2 days after DTaP and IPV given in left thigh parent said left leg has been swollen, less in morning, worse at night so that pajama couldn't be snapped on that side, no fever, no redness, no pain, no injury, no warmth, uses leg fine, just came in today for first visit for us to see.
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Feb-2021 at 2:23 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 12-Feb-2021 at 2:23 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The age of patient was provided as 83.39  Concomitant products were not provided.  On 12-Feb-2021 Excursion time was reported at 10 am and 11 am  with temperature as 35 and 35 degrees Fahrenheit respectively ,condition of vaccine prior to administration was not frozen, vaccine was moved to fridge on 09-Feb-2021, vial was moved to clinic on 12-Feb-2021. 3 vials were sent to clinic. Vaccine BUD date was 10-Mar-2021.  Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration.  Temperature recordings were taken using a traceable temperature monitor at every hour.  After administration, the vial was returned to the freezer/refrigerator, or maintained at room temperature.  It was reported that the patient was administered with vaccines that experienced more than 1 temperature excursion during 33 weeks on 2021. The HCP explained that each time a vial was put into a cooler, there was a period of time of 1 hour or 1 hour and a half approximately, when the temperature data logger registered 34 or 35 degree F.  Treatment medications were not reported.
Patient fainted after gave vaccination 1:30 pm. Pt awake and oriented x3 and vital signs normal. Pt went home with Father. Called Home Father states "she is doing fine. She went to shopping with Mother.
Urinary Tract Infection; soreness in the injection site; slight fever of 100.5; This spontaneous case was reported by a consumer and describes the occurrence of URINARY TRACT INFECTION (Urinary Tract Infection), INJECTION SITE PAIN (soreness in the injection site) and PYREXIA (slight fever of 100.5) in a 70-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 048A21A and 015MZ0A) for COVID-19 vaccination.     No Medical History information was reported.   On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 10-Mar-2021, the patient experienced INJECTION SITE PAIN (soreness in the injection site) and PYREXIA (slight fever of 100.5). On an unknown date, the patient experienced URINARY TRACT INFECTION (Urinary Tract Infection). The patient was treated with PARACETAMOL (TYLENOL) ongoing since an unknown date at a dose of 1 dosage form and SULFAMETHOXAZOLE, TRIMETHOPRIM (BACTRIM) ongoing since an unknown date at a dose of UNK mg. On 12-Mar-2021, INJECTION SITE PAIN (soreness in the injection site) and PYREXIA (slight fever of 100.5) had resolved. At the time of the report, URINARY TRACT INFECTION (Urinary Tract Infection) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 10-Mar-2021, Body temperature: 100.5 (High) fever-100.5.         Action taken in response to mRNA-1273 was not applicable.   This case was linked to MOD-2021-044569 (Patient Link).
Child's left leg, where vaccine given, swollen, red, increased by 2 1/2 induration and warm to touch. TX: Benadryl and ointment.
received the 2 doses of Pfizer vaccine on 12/30/2020 and 01/20/2021 and tested positive for COVID-19 on 08/16/2021
Information has been received from a lawyer regarding a case in litigation concerning a female patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. On 09-JUL-2014 the patient was vaccinated with ZOSTAVAX, 1 DF, (lot# and route unknown) as recommended for routine adult health maintenance and for the prevention of shingles. The vaccine did not prevent shingles as intended, but rather caused the patient to contract a persistent strain of herpes zoster. On or about 16-MAR-2016, the patient was treated by a physician for the onset of a vesicular rash accompanied by weakened immune symptoms, which was diagnosed as herpes zoster or shingles. The patient was prescribed acyclovir and oxycodone and PERCOCET for management of her symptoms and pain. As a direct and proximate result of these malfunctions, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, pain and suffering, and other damages. Additional information has been requested.
1 day post vaccine "bump appeared at vaccine site. Progressed to about 1" round raised rash. Examined 3 day post vaccine no vesicles, raised rash with surrounding cellulitis.
Severe headache, fever initially, body aches, followed by joint/knee pain in both knees.  Headache/fever subsided after 2 days but joint/knee pain severity has increased in both knees  and the pain is unbearable.  I am barely able to walk as of today (4/10/2021). Never in my life had i ever experienced any joint/knee pain.
This case was considered medically important for autism (OMIC). Information regarding Prevnar was received from a pharmacist, the mother of a female patient who in April 2005, at 18 months of age, received a fourth dose of Prevnar and subsequently, on an unspecified date in 2005, was diagnosed with autism. The patient has a past history of one ear infection and viral infections (reported as several viral infections in past). Indication for Prevnar was immunization. Product was administered in April 2005. Dose regimen was 1 dose 1 time per day (IM). Additional suspect medication included Hib-Titer vaccine administered in January 2005. Concomitant medications were not reported. In April 2005, at 18 months of age, the patient received a fourth dose of Prevnar. The child's right shoulder was noted to be red and swollen following the injection. Within a few days post vaccination, the patient was withdrawing from her family, pacing on her tiptoes, and her arms were flopping. On an unspecified date, she was diagnosed as autistic. The reporter indicated, "the physician was aware of the events." The patient's outcome is unknown. The reporter declined to grant permission for follow up. No additional information was available at the time of this report.
Received 2nd dose less than 25 days after receiving 1st dose; This spontaneous case was reported by a nurse and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received 2nd dose less than 25 days after receiving 1st dose) in a 35-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 26-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received 2nd dose less than 25 days after receiving 1st dose). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received 2nd dose less than 25 days after receiving 1st dose) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   no concomitant medications were reported. No treatment details were reported.
Patient presented today to pharmacy with a large, warm, red spot on the arm. The area was not raised or blistered. The skin was not broken. The patient reported symptoms of a low grade fever. The redness started two days after vaccination along with the fever. Upon reading the VIS to her, she was content that this was a fairly normal reaction to the vaccine. The patient also reported that the site improved drastically with Ibuprofen therapy and intermittent ice exposure to the site. The pharmacist on duty requested that the patient check back in with him later and the patient indicated that there had been even more improvement since this morning.
2nd vaccination  Chills lasting approximately 6-8 hrs Severe headache and body aches lasting approximately 48 hrs soreness at injection site lasting 36 hrs
PNEUMOVAX23 was administered in left shoulder. Pt reports no pain for first few hours but about 4 hours after administration pt started to feel feverish and injection site started to become sore. Pt reported fever of 101.3 and arm swollen around upper area where shot was given. Remained sore through the night and pt revisited pharmacy around 11:30AM following day of shot. Around injection site skin was pink and swollen and tender but other symptoms had subsided for patient.
pt recv vax 5APR96 & 25JUL97 pt to MD w/20 lesions consistent w/zoster on rt axillary area & a temp of 100;rash was described as erythematous w/few pustules;
Dizziness; Sleepiness; Could not eat or drink for 4 days; Nausea; Vomiting; Headache; Chills; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizziness), SOMNOLENCE (Sleepiness), DECREASED APPETITE (Could not eat or drink for 4 days), NAUSEA (Nausea) and VOMITING (Vomiting) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 023M20a) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event (No Historical condition reported.).    In February 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In February 2021, the patient experienced DIZZINESS (Dizziness), SOMNOLENCE (Sleepiness), DECREASED APPETITE (Could not eat or drink for 4 days), NAUSEA (Nausea), VOMITING (Vomiting), HEADACHE (Headache) and CHILLS (Chills). At the time of the report, DIZZINESS (Dizziness), SOMNOLENCE (Sleepiness), DECREASED APPETITE (Could not eat or drink for 4 days), NAUSEA (Nausea), VOMITING (Vomiting), HEADACHE (Headache) and CHILLS (Chills) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided.  No treatment details were provided.
Body ache; Feeling ache in neck as well as shoulder; Nausea; headache; fatigue; Fever; Feeling ache in neck as well as shoulder; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Body ache), NECK PAIN (Feeling ache in neck as well as shoulder), NAUSEA (Nausea), HEADACHE (headache) and FATIGUE (fatigue) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 036AL1A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Mar-2021, the patient experienced PAIN (Body ache), NECK PAIN (Feeling ache in neck as well as shoulder), NAUSEA (Nausea), HEADACHE (headache), FATIGUE (fatigue), PYREXIA (Fever) and ARTHRALGIA (Feeling ache in neck as well as shoulder). The patient was treated with NAPROXEN SODIUM (ALEVE) at a dose of UNK dosage form. In March 2021, NAUSEA (Nausea) and HEADACHE (headache) had resolved. At the time of the report, PAIN (Body ache), NECK PAIN (Feeling ache in neck as well as shoulder), FATIGUE (fatigue) and ARTHRALGIA (Feeling ache in neck as well as shoulder) had not resolved and PYREXIA (Fever) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Fatigue 10 hours after vaccine, shiver/chills 12 hours after vaccine. side effects subsided after 12 hours. Soreness at injection site. Continuing.
Vaccine given at 1600 on 10/13/2004. On 10/01/2004, patient developed temp in the AM while at school. Felt nauseated and vomited. Spectator said she "passed out" and was incontinent of urine. Injection only lasted a minute or so. No further incidents. Right arm has area of redness of 1.5x1.5 inches.
PARENT REPORTED INCREASED SWELLING IN LEFT ARM WITH PAIN, REDNESS, AND WARM TO TOUCH ON 04/19/2008. ON 04/20/2008 PARENT REPORTED A DECREASE IN SWELLING BUT STILL RED AND PAINFUL. PATIENT WAS SEEN IN OFFICE ON 04/20/2008 AND DIAGNOSED WITH CELLULITIS AT THE ABOVE MENTIONED SITE. PATIENT WAS PRESCRIBED CLINDAMYCIN AND WARM COMPRESSES TO AREA.
Immediately developed a bad deep sinus infection, uncontrollable crying, and eventually Sjogrens syndrome has developed.
no tx severe pain, swelling, redness & fever 16DEC84-31DEC84 persisted to 18JAN85;seen in hosp & rxn documented as compatible w/rubella vaccine rxn;caused chronnic arthritis;polyarthritis & then in 1992 devel RA;
Pt received MMR and Varicella vaccines and immedicately developed redness and swelling at both injection sites and hives on abdomen. No respiratory distress noted. Given single dose of benadryl with resolution of sxs
Harsh side effects; Vision got bad; Left arm is started swollen up; Hot; Little bumps all over; Couldn't eat anything; Couldn't even stand; Constipation; Difficulty breathing; Can't concentrate; Tremendous headaches; Felt nauseated; Aches and pain in every joint; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 09-Apr-2021 and was forwarded to Moderna on 09-Apr-2021.    This spontaneous case was reported by a consumer and describes the occurrence of ADVERSE DRUG REACTION (Harsh side effects), VISUAL IMPAIRMENT (Vision got bad), PERIPHERAL SWELLING (Left arm is started swollen up), FEELING HOT (Hot) and SWELLING (Little bumps all over) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event. Concomitant products included LISINOPRIL, ERYTHROMYCIN, DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL A), HYDROCHLOROTHIAZIDE, HYDROCODONE and PARACETAMOL (TYLENOL) for an unknown indication.    On 06-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Apr-2021, the patient experienced ADVERSE DRUG REACTION (Harsh side effects), VISUAL IMPAIRMENT (Vision got bad), PERIPHERAL SWELLING (Left arm is started swollen up), FEELING HOT (Hot), SWELLING (Little bumps all over), FEEDING DISORDER (Couldn't eat anything), WALKING DISABILITY (Couldn't even stand), CONSTIPATION (Constipation), DYSPNOEA (Difficulty breathing), DISTURBANCE IN ATTENTION (Can't concentrate), HEADACHE (Tremendous headaches), NAUSEA (Felt nauseated) and ARTHRALGIA (Aches and pain in every joint). At the time of the report, ADVERSE DRUG REACTION (Harsh side effects), VISUAL IMPAIRMENT (Vision got bad), PERIPHERAL SWELLING (Left arm is started swollen up), FEELING HOT (Hot), SWELLING (Little bumps all over), FEEDING DISORDER (Couldn't eat anything), WALKING DISABILITY (Couldn't even stand), CONSTIPATION (Constipation), DYSPNOEA (Difficulty breathing), DISTURBANCE IN ATTENTION (Can't concentrate), HEADACHE (Tremendous headaches), NAUSEA (Felt nauseated) and ARTHRALGIA (Aches and pain in every joint) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment for the event included diphenhydramine (Benadryl) and paracetamol (Tylenol).
Itching and feeling off over a week post second dose. The following day I was extremely tired and weak. By that evening, day 9 or 10, I began vomiting  followed by horrible diarrhea that lasted about 12 hours. I never thought it was related to the vaccine until I heard from others that had the same symptoms days after their vaccine.
Person received vaccine thru a Drive Thru clinic and they were underage. No obvious medical distress noted post vaccination.
rash that started around the site and spread over his entire body. lasted 3 months was itchy and seen several times in office
Patient had extreme trouble breathing for approximately 1/2 hour. Later had 101+ fever and dizziness lasting until approximately 4:00 AM.
A report has been received from a Health Professional concerning a 6 year old, female patient. The relevant history and concomitant drugs of patient were not reported. The patient has been receiving nasal FLUMIST. FLUMIST started on 07-Nov-2012. The Health Professional reported that the patient has Influenza A virus infection which started on 16-Jan-2013 after administration of FLUMIST by the nurse. She was treated with TAMIFLU. The nurse commented that the lot for this patient's FLUMIST vaccination did not seem right. The patient recovered from the event of tested positive for Flu A on an unspecified date. The reporter considered the event of tested positive for Flu A to be non-serious. Summary of follow-up information received on 11-Feb-2013: reporter last name was added, new lot number and expiration date was added.